Discontinued — last reported Q1 '26
Janumet — Sales
Merck & Co. Janumet — Sales decreased by 47.9% to $207.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 58.1%, from $494.00M to $207.00M. Over 4 years (FY 2021 to FY 2025), Janumet — Sales shows a downward trend with a -16.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption or successful pricing strategies for the product, while a decrease may signal increased generic competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific oral anti-diabetic medication product...
Peer comparison
Comparable to revenue metrics for specific branded pharmaceutical products or therapeutic franchises at other large-cap biopharmaceutical companies.
mrk_segment_janumet_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $954.00M | $974.00M | $1.03B | $908.00M | $952.00M | $834.00M | $705.00M | $657.00M | $708.00M | $509.00M | $480.00M | $502.00M | $449.00M | $409.00M | $510.00M | $494.00M | $503.00M | $486.00M | $397.00M | $207.00M |
| QoQ Change | — | +2.1% | +5.6% | -11.8% | +4.8% | -12.4% | -15.5% | -6.8% | +7.8% | -28.1% | -5.7% | +4.6% | -10.6% | -8.9% | +24.7% | -3.1% | +1.8% | -3.4% | -18.3% | -47.9% |
| YoY Change | — | — | — | — | -0.2% | -14.4% | -31.5% | -27.6% | -25.6% | -39.0% | -31.9% | -23.6% | -36.6% | -19.6% | +6.3% | -1.6% | +12.0% | +18.8% | -22.2% | -58.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s janumet — sales?
- Merck & Co. (MRK) reported janumet — sales of $207.00M in Q1 2026.
- How has Merck & Co.'s janumet — sales changed year-over-year?
- Merck & Co.'s janumet — sales decreased by 58.1% year-over-year, from $494.00M to $207.00M.
- What is the long-term trend for Merck & Co.'s janumet — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s janumet — sales has grown at a -16.8% compound annual growth rate (CAGR), from $3.93B to $1.88B.
- What does janumet — sales mean?
- The total revenue generated from the sales of the Janumet product line.